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Background: To evaluate the on-going scale-up of HIV programs, we assessed trends in patient characteristics at
enrolment and ART initiation over 7 years of implementation.
Methods: Data were from Optimal Models, a prospective open cohort study of HIV-infected (HIV+) adults
(≥15 years) and children (<15 years) enrolled from January 2005 to December 2011 at 44 HIV clinics in 3 regions of
mainland Tanzania (Kagera, Kigoma, Pwani) and Zanzibar. Comparative statistics for trends in characteristics of pa-
tients enrolled in 2005–2007, 2008–2009 and 2010–2011 were examined.
Results: Overall 62,801 HIV + patients were enrolled: 58,102(92.5%) adults, (66.5% female); 4,699(7.5%) children.
Among adults, pregnant women enrolment increased: 6.8%, 2005–2007; 12.1%, 2008–2009; 17.2%, 2010–2011; as
did entry into care from prevention of mother-to-child HIV transmission (PMTCT) programs: 6.6%, 2005–2007; 9.5%,
2008–2009; 12.6%, 2010–2011
. WHO stage IV at enrolment declined: 27.1%, 2005–2007; 20.2%, 2008–2009; 11.1% 2010–2011. Of the 42.5% and
29.5% with CD4+ data at enrolment and ART initiation respectively, median CD4+ count increased: 210 cells/μL,
2005–2007; 262 cells/μL, 2008–2009; 266 cells/μL 2010–2011; but median CD4+ at ART initiation did not change
(148 cells/μL overall). Stavudine initiation declined: 84.9%, 2005–2007; 43.1%, 2008–2009; 19.7%, 2010–2011.
Among children, median age (years) at enrolment decreased from 6.1(IQR:2.7-10.0) in 2005–2007 to 4.8(IQR:1.9-8.6)
in 2008–2009, and 4.1(IQR:1.5-8.1) in 2010–2011 and children <24 months increased from 18.5% to 26.1% and 31.5%
respectively. Entry from PMTCT was 7.0%, 2005–2007; 10.7%, 2008–2009; 15.0%, 2010–2011. WHO stage IV at
enrolment declined from 22.9%, 2005–2007, to 18.3%, 2008–2009 to 13.9%, 2010–2011. Proportion initiating
stavudine was 39.8% 2005–2007; 39.5%, 2008–2009; 26.1%, 2010–2011. Median age at ART initiation also declined
significantly.
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Conclusions: Over time, the proportion of pregnant women and of adults and children enrolled from PMTCT
programs increased. There was a decline in adults and children with advanced HIV disease at enrolment and
initiation of stavudine. Pediatric age at enrolment and ART initiation declined. Results suggest HIV program
maturation from an emergency response.
Keywords: ART program, HIV-infected adults, HIV-infected children, Trends at enrolment, Trends at ART initiation,
TanzaniaBackground
In the United Republic of Tanzania (Tanzania), HIV preva-
lence among adults aged 15–49 years was last estimated at
5.7% in 2008/2009 [1]. An estimated 1,400,000 people were
living with HIV by 2010, of whom 200,000 are children
under 15 years of age [2]. Approximately 610,000 persons
living with HIV were in need of antiretroviral therapy (ART)
[2] using the ART eligibility criteria in the 2006 World
Health Organization (WHO) guidelines [3]. ART coverage
was estimated at 42% among adults and 18% among chil-
dren, and Tanzania was one of five countries (together with
Nigeria, South Africa, Kenya, and Uganda) that contributed
to 50% of the global unmet need for pediatric ART [4]. To
address the HIV epidemic, Tanzania has been providing free
HIV care and treatment, including antiretroviral therapy
(ART) since 2004. Over 900 clinics provide ART in the
country [5] and 258,069 patients were receiving ART by the
end of 2010 [4].
The scale-up of ART services and the large number
of patients receiving ART are important successes in
Tanzania. An evaluation conducted in the early years of pro-
gram implementation revealed that ART services had been
introduced at 210 facilities within 3 years, but there was
limited male and pediatric enrolment [5]. Like many sub-
Saharan African countries, Tanzania’s HIV services were ini-
tiated at urban higher-level health facilities and prioritized
patients with the most advanced HIV disease [6]. Over
time, there have been efforts to encourage HIV testing,
decentralize HIV services, expand prevention of mother-to-
child HIV transmission (PMTCT) programs, increase the
number of people receiving HIV care and treatment, and
phase out the use of stavudine due to significant toxicity
[7-9]. In order to inform the continuing scale-up of ART
programs in this country, we examined trends over 7 years
in characteristics of adults and children attending HIV care
and treatment clinics in selected regions of Tanzania.Methods
Setting
ICAP at Columbia University with funding from the
United States President’s Emergency Plan for AIDS Re-
lief (PEPFAR) provided programmatic, health facility and
health systems support to Tanzania in the establishment
of HIV care and treatment clinics (CTCs). ICAP’ssupport in Tanzania began in 2004 and was regionalized
to Kagera, Kigoma (north-west Tanzania), Pwani (east
coastal region), and the island of Zanzibar. In 2007–
2008, HIV prevalence among adults aged 15–49 years in
these regions was estimated at 5.3% in Pwani, 3.4% in
Kagera, 0.9% in Kigoma and 0.6% in Zanzibar. By De-
cember 2011, a total of 127 CTCs had been supported in
these regions and a total of 89,780 HIV-infected patients
enrolled into HIV care [10]. ICAP support included
training of health care providers, building capacity for
sustainable clinical mentorship and supervision, and im-
plementation of the national monitoring and evaluation
(M&E) system for HIV care and treatment. The Identify-
ing Optimal Models of Care and Treatment in sub-
Saharan Africa (Optimal Models) study was funded by
the Centers for Disease Control and Prevention (CDC)
to analyze routinely collected patient and site-level data
for program evaluation. Optimal Models is an open co-
hort, with patients entering and exiting according to
their routine care.Routinely collected patient-level data
When patients attend HIV care and treatment clinics,
demographic and clinical characteristics and treatment de-
tails e.g. age, gender, source of referral, WHO staging, CD4
+ cell count (CD4+), ART status and regimen are recorded
on their patient medical card. During the study observation
period, ART initiation was according to national guidelines
which aligned with the 2003 and 2006 WHO ART initi-
ation guidelines [3,6,8,11]. The data were entered into a
Ministry of Health Microsoft Access database, which is
maintained at the site level, updated with every patient
visit, and used for reporting to the national government
and implementation partners. Implementation of the
patient-level database in ICAP-supported regions was pri-
oritized at clinics with the highest patient volume. By the
end of 2011, the database was in use at 44 clinics and cap-
tured 70% of all patients ever enrolled across the 127
clinics. At the time of introduction of the database, all
retrospective data were entered into the database. Quar-
terly supervision visits were conducted by ICAP in collab-
oration with Ministry of Health Regional and District
Health Management Teams to support site-level data entry
clerks in data quality assurance.
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Health facility and program characteristics were cap-
tured annually using a site assessment tool [12,13]. Data
collected include the site characteristics e.g. location of
the site and level of health facility (health centers and
dispensaries were categorized as primary facilities; and
district, missionary or regional referral hospitals as sec-
ondary. Program characteristics that describe the ser-
vices provided (e.g. presence and location of Voluntary
Counseling and Testing (VCT), PMTCT and CD4+ test-
ing services) were also documented. Data from the most
recent survey (2011) were used to give a descriptive
snap-shot of site and program characteristics.
Data analysis
The patient record data were de-identified and anonymized,
then combined across health facilities to create an analytic
dataset. The analysis (using SPSS 18) explored trends in pa-
tient characteristics among adults (≥15 years) and children
(<15 years) enrolled from January 2005 to December 2011.
Seven patients were missing age data and excluded from the
analysis. WHO stage and CD4+ at enrolment and ART initi-
ation, respectively, were based on records within < 90 days
before and < 30 days after date of enrolment/ART initiation
with priority given to data before and closest to the enrol-
ment/ART initiation date. ART eligibility was defined using
the 2006 WHO guidelines [14]. Descriptive comparative sta-
tistics were computed for differences in characteristics of pa-
tients enrolled in 2005–2007, 2008–2009 and 2010–2011.
These time categories were estimated to represent particular
phases of the ART program in Tanzania: the early start-up
phase in 2005–2007 where ART services were introduced
starting at major hospitals; the rapid scale-up and
decentralization phase in 2008–2009 where ART was rolled
out to a large number of clinics including lower level health
facilities; and a maturation phase 2010–2011 where fewer
clinics were newly implementing ART services and the focus
for existing clinics was ensuring sustainability and enhancing
service provision through support services. Differences and
trends in patient characteristics between time categories were
tested using chi-square tests for categorical variables and
generating linear-by-linear association p values. Differences
in medians over time groups were tested with the
Jonckheere-Terpstra test, and for other nominal variables like
gender and source of referral, the Kruskal-Wallis test was
used. Adult trends in WHO stage and CD4+ were stratified
by gender and pregnancy status. Missing data are an import-
ant focus area for data quality improvement, so for variables
with >5% missing data, tables include an indication for data
available for each variable with a test for trend over time.
Ethical approval
Optimal Models involves analysis of de-identified rou-
tinely collected data and received non-human subjectsresearch determination from Columbia University Insti-
tutional Review Board and the Centers for Disease Con-
trol. The study was also approved by Institutional
Review Boards in mainland Tanzania and Zanzibar.
Results
A total of 62,801 patients, 58,102 (92.5%) adults and 4,699
(7.5%) children, were enrolled at the 44 clinics, with peak
enrolment in 2009 (Figure 1). The majority of patients
(58.0%) and half the clinics were from Kagera region
(Table 1). Most patients (80.9%) attended urban/semi-
urban clinics, where 79.5% of the clinics were located.
Nearly half of the patients (46.1%) were enrolled at the
29.5% public secondary health facilities, while 22.4% were
enrolled at the 36.4% public primary health clinics. VCT
and PMTCT services were available at all but 1 clinic, and
all patients were enrolled at clinics that provided antenatal
services and CD4+ testing on or off-site.
Adult (≥15 years) characteristics
At enrolment, 66.5% were female and 12.5% of these
were pregnant (Table 2). The overall median age was
35.2 years (yrs) (IQR 29.1-42.4). Median age of men
(38.8 yrs, IQR 32.5-45.9) was significantly higher than
non-pregnant women (33.4 yrs, IQR 27.7-40.2) and
pregnant women (28.2 yrs, IQR 24.1-32.6). Half the
adults (52.3%) were enrolled from VCT programs, 9.9%
from PMTCT and 9.3% transferred in from other clinics.
Overall, 84.4% adults had a WHO clinical stage recorded
at enrolment, of whom 17.9% had advanced HIV disease
with WHO stage IV. Among the 42.5% adults with doc-
umented CD4+ at enrolment, the overall median CD4+
was 251 cells/μL (IQR 104–463); and it was significantly
higher among adults from PMTCT (432 cells/μL, IQR
254–620) compared with VCT (257 cells/μL, IQR 109–
472) and other referral points (212 cells/μL, IQR 86–
420); a difference that remained statistically significant
after stratifying by gender and pregnancy status (data
not shown). Only 29.5% of adults had documented CD4
+ at ART initiation and median CD4+ was 148 cells/μL
(IQR 67–236). Nearly half (49.2%) of the adults initiated
ART across the 7 year period, and of these 58.2% were
prescribed stavudine in the initial ART regimen.
Trends in adult characteristics
Among females, the proportion pregnant at enrolment
increased from 6.8% in 2005–2007 to 12.1% in 2008–
2009 and 17.2% in 2010–2011 (p < 0.0001) (Table 2).
Overall, adult median age at enrolment decreased mod-
estly from 36.1 (IQR 30.0-43.1) in 2005–2007 to 35.0
(IQR 28.9-42.1) in 2008–2009 and 34.8 (IQR 28.5-42.1)
in 2010–2011 (p < 0001). On stratifying by gender and
pregnancy status, the decrease in median age over time
only remained statistically significant among non-
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Figure 1 Enrolment of children and adults (men, pregnant women and non-pregnant women) by calendar year in Tanzania (2005–2011).
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entry into care contributed 37.6% of HIV + adults in
2005–2007, 56.8% in 2008–2009 and 57.8% in 2010–2011,
p < 0.0001. There were also increasing proportions of
adults enrolled from PMTCT programs over time: 6.6% in
2005–2007; 9.5% in 2008–2009; and 12.6% in 2010–2011.
The proportion of adults transferring in from other clinics
increased from 4.2% in 2005–2007 to 12.2% in 2008–
2009, then declined to 10.0% in 2010–2011, though the
overall proportion was increasing over time, p < 0.0001.Table 1 Clinic and program characteristics, and number of ad
treatment clinics in Tanzania (2011)
Cli
N = 44
Region Kagera 22
Kigoma 5
Pwani 12
Zanzibar1 5
Location Urban/Semi-Urban 35
Rural 9
Facility Level Public Primary 16
Public Secondary2 13
Private 15
VCT services available at clinic Yes 43
PMTCT services available at clinic Yes 43
Availability of CD4+ testing On-site 21
Off-site3 23
Availability of infant diagnostic testing DBS collected lab at another
facility
42
Not available 2
1Excludes data from the national referral hospital. 2Includes 1 tertiary facility in Zanzib
analyzed at a laboratory outside the health facility and the results returned to the CTCThere was an increase in WHO clinical stage docu-
mentation from 62.0%, 2005–2007 to 89.8%, 2006–2007,
to 95.4%, 2010–2011 (p < 0.0001). The percentage of
adults enrolled with WHO clinical stage IV declined
from 27.1% in 2005–2007 to 20.2% in 2008–2009 and
11.1% in 2010–2011 (p < 0.0001). This decline was statis-
tically significant among males as well as non-pregnant
and pregnant women (Figure 2). Overtime, a slightly
higher proportion of adults had CD4+ documentation at
enrolment: 39.6%, 2005–2007; 44.0%, 2008–2009; 43.2%,ults and children ever enrolled at the study HIV care and
nics Adults
attending clinics
Children
attending clinics
All patients
attending clinics
(%) N = 58,102 (%) N = 4,699 (%) N = 62,801 (%)
(50.0) 33952 (58.4) 2479 (52.8) 36431 (58.0)
(11.4) 7194 (12.4) 714 (15.2) 7908 (12.6)
(27.3) 15453 (26.6) 1359 (28.9) 16812 (26.8)
(11.4) 1503 (2.6) 147 (3.1) 1650 (2.6)
(79.5) 46969 (80.8) 3830 (81.5) 50799 (80.9)
(20.5) 11133 (19.2) 869 (18.5) 12002 (19.1)
(36.4) 13065 (22.5) 997 (21.2) 14062 (22.4)
(29.5) 26679 (45.9) 2260 (48.1) 28939 (46.1)
(34.1) 18358 (31.6) 1442 (30.7) 19800 (31.5)
(97.7) 57590 (99.1) 4671 (99.4) 62261 (99.1)
(97.7) 57942 (99.7) 4689 (99.8) 62631 (99.7)
(47.7) 42292 (72.8) 3522 (75.0) 45814 (73.0)
(52.3) 15810 (27.2) 1177 (25.0) 16987 (27.0)
(95.5) 57479 (98.9) 4644 (98.8) 62123 (98.9)
(4.5) 623 (1.1) 55 (1.2) 678 (1.1)
ar. 3Off-site means blood is collected at care and treatment clinic (CTC), CD4+
where they are picked by the patient.
Table 2 Characteristics at enrolment and ART initiation of adults attending HIV clinics Tanzania by calendar year
group
All adults Adult characteristics by year of enrolment
All years 2005-2007 2008-2009 2010-2011 p value for
trendN = 58,102 N = 15,392 N = 22,289 N = 20,421
n (%) n (%) n (%) n (%)
Gender1 Male 19467 (33.5) 5033 (32.7) 7498 (33.6) 6936 (34.0) 0.02
Female 38634 (66.5) 10358 (67.3) 14791 (66.4) 13485 (66.0)
Females pregnant at enrolment2 4816 (12.5) 704 (6.8) 1793 (12.1) 2319 (17.2) <0.0001
Age at enrolment (years) 15-19 years 1748 (3.0) 399 (2.6) 725 (3.3) 624 (3.1) <0.0001
20-29 years 14985 (25.8) 3416 (22.2) 5897 (26.5) 5672 (27.8)
30-39 years 22683 (39.0) 6165 (40.1) 8733 (39.2) 7785 (38.1)
10-49 years 12693 (21.8) 3838 (24.9) 4667 (20.9) 4188 (20.5)
50+ years 5993 (10.3) 1574 (10.2) 2267 (10.2) 2152 (10.5)
Point of entry into HIV care Point of entry documented 53739 (92.5) 13405 (87.1) 21027 (94.3) 19739 (92.5) <0.0001
VCT 28126 (52.3) 5035 (37.6) 11943 (56.8) 11148 (57.8) <0.0001
PMTCT 5311 (9.9) 887 (6.6) 1993 (9.5) 2431 (12.6)
Other3 20295 (37.8) 7483 (55.8) 7091 (33.7) 5721 (29.6)
Transferred in Yes 5398 (9.3) 643 (4.2) 2720 (12.2) 2035 (10.0) <0.0001
WHO stage at enrolment WHO stage documented 49048 (84.4) 9545 (62.0) 20018 (89.8) 19485 (95.4) <0.0001
I 12593 (25.7) 1615 (16.9) 4742 (23.7) 6263 (32.0) <0.0001
II 13309 (27.1) 1901 (19.9) 5117 (25.6) 6291 (32.3)
III 14368 (29.3) 3445 (36.1) 6121 (30.6) 4802 (24.6)
IV 8778 (17.9) 2584 (27.1) 4038 (20.2) 2156 (11.1)
CD4+ at enrolment4 CD4+ documented 24713 (42.5) 6093 (39.6) 9804 (44.0) 8816 (43.2) <0.0001
(cells/μL) <50 3467 (14.0) 981 (16.1) 1294 (13.2) 1192 (13.5) <0.0001
50-99 2464 (10.0) 718 (11.8) 918 (9.4) 828 (9.4)
100-199 4494 (18.2) 1241 (20.4) 1737 (17.7) 1516 (17.2)
200-349 5113 (20.7) 1217 (20.0) 2044 (20.8) 1852 (21.0)
≥350 9175 (37.1) 1936 (31.8) 3811 (38.9) 3428 (38.9)
ART eligibility at enrolment5 Eligible 18464 (31.8) 5273 (34.3) 7601 (34.1) 5590 (27.4) <0.0001
Not eligible 26151 (45.0) 4373 (28.4) 10059 (45.1) 11719 (57.4)
Unknown eligibility 13487 (23.2) 5746 (37.3) 4629 (20.8) 3112 (15.2)
CD4+ at ART initiation4, (cells/μL) CD4+ documented 17142 (29.5) 5086 (33.0) 6945 (31.2) 5111 (25.0) <0.0001
<50 3379 (19.7) 1020 (20.1) 1307 (18.8) 1052 (20.6) <0.0001
50-99 2597 (15.1) 803 (15.8) 982 (14.1) 812 (15.9)
100-199 5319 (31.0) 1638 (32.2) 2132 (30.7) 1549 (30.3)
200-349 4421 (25.8) 1255 (24.7) 1888 (27.2) 1278 (25.0)
≥350 1426 (8.3) 370 (7.3) 636 (9.2) 420 (8.2)
Started ART All adults who started ART 28578 (49.2) 9304 (60.4) 11164 (50.1) 8110 (39.7) <0.0001
Females who started ART6 18445 (64.5) 6190 (66.5) 7199 (64.5) 5056 (62.3) <0.0001
Pregnant at ART initiation7 504 (2.7) 111 (1.8) 211 (2.9) 182 (3.6) <0.0001
First ART regimen8 Stavudine containing 16635 (58.2) 7900 (84.9) 7139 (63.9) 1596 (19.7) <0.0001
Zidovudine containing 11086 (38.8) 1338 (14.4) 3894 (34.9) 5854 (72.2)
Other9 857 (3.0) 66 (0.7) 131 (1.2) 660 (8.1)
11 adult missing gender data. 2Denominator for percentage is females enrolled. 3I TB/HIV clinics, inpatient clinics, outpatient clinics, and Persons Living with HIV
associations .4CD4+ at any date < 90 days before or < 30 days after date of enrolment/ART initiation with priority given to date before and closest to the enrolment/ART
initiation date. 5Based on 2006 WHO eligibility criteria.6Denominator for percentage is all adults who started ART. 7Denominator for percentage is females who started
ART. 8Denominator for percentage is those who started ART, stavudine and zidovudine containing regimens were combined with lamivudine and nevirapine or
efavirenz. 9Includes less commonly used drugs like abacavir, tenofovir and protease inhibitors.
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Figure 2 Changes over time in adult WHO stage at enrolment by gender and pregnancy status in Tanzania.
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http://www.biomedcentral.com/1471-2458/13/10162010–2011, but there was a decline in CD4+ documen-
tation at ART initiation 33.0%, 2005–2007; 31.2%, 2008–
2009; 25.0%, 2010–2011, (p < 0.0001). In the sub-set of
adults with CD4+, median CD4+ at enrolment increased
from 210 cells/μL (IQR 88–418) in 2005–2007 to 262
cells/μL (IQR 111–484) in 2008–2009 and 266 cells/μL
(IQR 112–468) in 2010–2011 (p < 0001). On stratifying
by gender and pregnancy status, this increase was only
statistically significant among the non-pregnant women
(Figure 3). There were no statistically significant changes
in median CD4+ at ART initiation even after stratifying
by gender and pregnancy status (Figure 3). Median CD4
+ at ART initiation was 143 cells/μL (IQR 65–225) in
2005–2007, 155 cells/μL (IQR 70–245) in 2008–2009
and 143 cells/μL (IQR 63–235) in 2010–2011, p = 0.6.
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Figure 3 Changes over time in adult median CD4+ and inter-quartile
pregnancy status.that initiated ART, 84.9%, 63.9% and 19.7% of those en-
rolled in 2005–2007, 2008–2009, and 2010–2011 re-
spectively. A higher proportion of adults initiated AZT-
containing regimens: 14.4%, 34.9% and 72.2% in the re-
spective calendar year groups.
Pediatric (<15 years) characteristics
Overall, 52.8% were female and median age at enrolment
was 4.1 years (IQR 1.9-8.8), and at ART initiation
5.6 years (IQR 2.2-9.7). Main points of entry into care
were VCT (44.4%) and PMTCT (11.2%); and 10.8% of
children transferred in from other clinics (Table 3). The
majority (85.5%) had documented WHO clinical stage at
enrolment and 17.6% were stage IV. Nearly half (49.3%)
were ≥5 years and of these, 40.6% and 28.5% had CD4+
at enrolment and ART initiation documentedregnant 
men
Pregnant women
range at enrolment and ART initiation by gender and
Table 3 Characteristics at enrolment and ART initiation of children attending HIV clinics Tanzania by calendar year
group
All
children
Pediatric characteristics by year of
enrolment
All years 2005-2007 2008-2009 2010-2011 p
value
for
trend
N = 4,699 N = 1,229 N = 1,877 N = 1,593
n (%) n (%) n (%) n (%)
Gender Female 2479 (52.8) 674 (54.8) 984 (52.4) 821 (51.5) 0.09
Male 2220 (47.2) 555 (45.2) 893 (47.6) 772 (48.5)
Age at enrolment (years) 0-1 years 1219 (25.9) 227 (18.5) 491 (26.1) 501 (31.5) <0.0001
2-4 years 1162 (24.7) 280 (22.8) 479 (25.5) 403 (25.3)
5-9 years 1431 (30.5) 413 (33.6) 586 (31.2) 432 (27.1)
10-14 years 887 (18.9) 309 (25.1) 321 (17.1) 257 (16.1)
Point of entry into HIV care Point of entry documented 4294 (91.4) 1066 (86.7) 1757 (93.6) 1471 (92.3) <0.0001
VCT 1908 (44.4) 356 (33.4) 867 (49.3) 685 (46.6) <0.0001
PMTCT 483 (11.2) 75 (7.0) 188 (10.7) 220 (15.0)
Other 1 1903 (44.3) 635 (59.6) 702 (40.0) 566 (38.5)
Transferred in Yes 506 (10.8) 54 (4.4) 249 (13.3) 203 (12.7) <0.0001
WHO stage at enrolment WHO stage documented 4017 (85.5) 816 (66.4) 1695 (90.3) 1506 (94.5) <0.0001
I 836 (20.8) 110 (13.5) 351 (20.7) 375 (24.9) <0.0001
II 1183 (29.4) 189 (23.1) 477 (28.1) 517 (34.3)
III 1291 (32.1) 330 (40.4) 557 (32.9) 404 (26.8)
IV 707 (17.6) 187 (22.9) 310 (18.3) 210 (13.9)
ART eligibility at enrolment2 Eligible 1936 (41.2) 468 (38.1) 810 (43.2) 658 (41.3) <0.0001
Not eligible 1447 (30.8) 284 (23.1) 607 (32.3) 556 (34.9)
Unknown eligibility 1316 (28.0) 477 (38.8) 460 (24.5) 379 (23.8)
Started ART Yes 2599 (55.3) 742 (60.4) 1045 (55.7) 812 (51.0) <0.0001
Age at ART initiation (years) 0-1 years 690 (26.5) 108 (14.6) 270 (25.8) 312 (38.4) <0.0001
2-4 years 576 (22.2) 150 (20.2) 249 (23.8) 177 (21.8)
5-9 years 799 (30.7) 266 (35.8) 338 (32.3) 195 (24.0)
10-14 years 534 (20.5) 218 (29.4) 188 (18.0) 128 (15.8)
First ART regimen3 Stavudine containing 920 (35.4) 295 (39.8) 413 (39.5) 212 (26.1) <0.0001
Zidovudine containing 1636 (62.9) 440 (59.3) 623 (59.6) 573 (70.6)
Other4 43 (1.7) 7 (0.9) 9 (0.9) 27 (3.3)
CD4+ at enrolment5 Number of children ≥5y 2318 - 722 - 907 - 689 -
(cells/μL), children ≥5 years CD4+ documented 941 (40.6) 282 (39.1) 364 (40.1) 295 (42.8) 0.15
<50 112 (11.9) 35 (12.4) 43 (11.8) 34 (11.5) 0.06
50-99 50 (5.3) 23 (8.2) 11 (3.0) 16 (5.4)
100-199 111 (11.8) 39 (13.8) 48 (13.2) 24 (8.1)
200-349 134 (14.2) 39 (13.8) 53 (14.6) 42 (14.2)
≥350 534 (56.7) 146 (51.8) 209 (57.4) 179 (60.7)
CD4+ at ART initiation5, (cells/μL), children ≥5 years CD4+ documented 660 (28.5) 219 (30.3) 276 (30.4) 165 (23.9) 0.007
<50 111 (16.8) 37 (16.9) 40 (14.5) 34 (20.6) 0.28
50-99 68 (10.3) 28 (12.8) 24 (8.7) 16 (9.7)
100-199 138 (20.9) 43 (19.6) 67 (24.3) 28 (17.0)
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Table 3 Characteristics at enrolment and ART initiation of children attending HIV clinics Tanzania by calendar year
group (Continued)
200-349 149 (22.6) 55 (25.1) 58 (21.0) 36 (21.8)
≥350 194 (29.4) 56 (25.6) 87 (31.5) 51 (30.9)
1Includes TB/HIV clinics, inpatient clinics, outpatient clinics, and Persons Living with HIV associations. 2Based on WHO 2006 guidelines. 3As a percentage of those who
started ART, stavudine and zidovudine containing regimens were combined with lamivudine and nevirapine or efavirenz. 4Includes less commonly used drugs in the
initial ART regimen like abacavir, tenofovir and protease inhibitors. 5CD4+ done at any date < 90 days before or < 30 days after date of enrolment/ART initiation with
priority given to date before and closest to the enrolment/ART initiation date.
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5 years or older was 398 cells/μL (IQR 167–717) and at
ART initiation 327 cells/μL (IQR 87–394). Overall,
55.3% initiated ART, of whom 35.4% were prescribed
stavudine in the initial ART regimen.
Trends in pediatric characteristics
Although absolute numbers of children increased, there
were no changes in the proportion of children over time:
7.4%, 2005–2007; 7.8%, 2008–2009; 7.4%, 2010–2011. The
children’s median age at enrolment decreased from 6.1 yrs
(IQR 2.7-10.0) in 2005–2007 to 4.8 yrs (IQR 1.9-8.6) in
2008–2009, and 4.1 yrs (IQR 1.5-8.1) in 2010–2011 (p <
0.0001). Children aged <24 months at enrolment increased
from 18.5% in 2005–2007 to 26.1% in 2008–2009 and
31.5% in 2010–2011, p < 0.0001, (Table 3). Referrals from
PMTCT clinics tended to be younger (Figure 4) and were
an increasing proportion of children over time: 7.0%, 2005–
2007; 10.7%, 2008–2009; 15.0%, 2010–2011, p < 0.0001,
(Table 3). The proportion of children transferring in from
other clinics increased from 4.4% in 2005–2007 to 13.3% in
2008–2009 then declined to 12.7% in 2010–2011, but an
overall upward trend was observed (p < 0.0001).
There was an increase in WHO clinical stage docu-
mentation from 66.4%, 2005–2007 to 90.3%, 2006–2007,0.00
5.00
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15.00
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Figure 4 Changes over time in children’s median age and inter-quart
HIV clinics in Tanzania.to 94.5%, 2010–2011. The percentage of children with
WHO clinical stage IV declined from 22.9%, 2005–2007
to 18.3%, 2008–2009 to 13.9%, 2010–2011 (p < 0.0001).
Among the 2,318 children ≥5 years, there was no statis-
tically significant change in documentation of CD4+ at
enrolment, and documentation of CD4+ at ART initi-
ation declined over time (Table 3). In this subset of the
5 years and older children with CD4+ at enrolment
(40.6%) and ART initiation (28.5%), median CD4+ at en-
rolment increased from 378 cells/μL (IQR 123–697) in
2005–2007 to 401 cells/μL (IQR 172–718) in 2008–2009
and 451 cells/μL (IQR 198–744) in 2010–2011 (p =
0.035), and median CD4+ at ART initiation was 208
cells/μL (IQR 81–350), 223 cells/μL (IQR 107–402) and
223 cells/μL (IQR 60–396) in the respective time periods
(p = 0.34). Of the 2,599 children that initiated ART,
39.8%, 39.5% and 26.1% of those enrolled in 2005–2007,
2008–2009, and 2010–2011 respectively initiated
stavudine-containing regimens (p < 0.0001). Median
pediatric age at ART initiation declined from 7.4 yrs
(IQR 4.0-11.1) in 2005–2007 to 5.5 yrs (IQR 2.3-9.3) in
2008–2009, and 3.7 yrs (IQR 1.4-8.1) in 2010–2011 (p <
0.0001). The proportion of children aged <24 months at
ART initiation increased from 14.6% in 2005–2007 to
25.8% in 2008–2009 and 38.4% in 2010–2011 (p <CT OTHER 
ile range at enrolment and ART initiation by source of referral to
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ated ART at a much younger age than those enrolled
from VCT and other referral points (Figure 4).
Discussion
We reviewed trends of adult and pediatric characteristics
at enrolment and ART initiation over 7 years of imple-
menting HIV care and treatment programs in the United
Republic of Tanzania. Our findings suggest that increas-
ingly, adults and children are being enrolled from
PMTCT programs and with less advanced HIV disease.
We found an increasing proportion of pregnant women
enrolled, younger age at enrolment among adults, youn-
ger age at enrolment and ART initiation among children,
and fewer adults and children starting stavudine in their
initial ART regimen. However, fewer than half the pa-
tients had CD4+ documentation and there were no
changes in median CD4+ at ART initiation among
adults and children. Overall, a large number of adults
and children accessed HIV care and treatment, demon-
strating the successful establishment and expansion of
HIV care and treatment programs in Tanzania. In the 3
ICAP supported regions of mainland Tanzania (Kagera,
Kigoma and Pwani), these data from sites with electronic
databases represent 43% of the adult population esti-
mated to be HIV+ by December 2009, implying that a
significant proportion of the population in these regions
had accessed HIV services [15]. Observed trends suggest
progression from an emergency response to more ma-
ture HIV programs.
Over time, PMTCT programs had an increasing con-
tribution to adults and children entering HIV care. This
is further evidenced by the significant increase in the
proportion of women pregnant at enrolment and may be
an indication that the scale up of PMTCT programs is
having a positive impact on linkage into care and treat-
ment. Though small, the proportion of women pregnant
at ART initiation also increased over time. The largest
contributor to adults and children entering HIV care
was VCT, particularly after 2007. This could reflect the
success of the National Voluntary HIV Testing Cam-
paign conducted in 2007/2008 [1]. The population was
encouraged to know their HIV status and subsequently
access HIV care and treatment, and it is possible that
there was increased population awareness of VCT in
subsequent years. The proportion of patients transfer-
ring into the study clinics peaked in 2008–2009, a period
associated with a rapid and peak increase in the number
of clinics with ART services and decentralization [16].
The declining proportion of patients enrolled with less
advanced HIV disease over time is an encouraging find-
ing, and may be linked to more referrals from VCT and
PMTCT clinics which are typically attended by healthier
patients as observed in our analysis and by others[17,18]. It could also reflect maturation of the Tanzanian
program which in the early years prioritized identifica-
tion and ART initiation of the patients with the most ad-
vanced HIV disease as specified in the national
guidelines [6].
There have been significant improvements in WHO
stage documentation over time, but CD4+ documenta-
tion remains low, even among the most recently enrolled
adults and children. As a result, ART eligibility at enrol-
ment could not be determined for at least 1 in five pa-
tients in the study population (with the exception of the
most recently enrolled adults). Considering the liberal
window attached to the enrolment visit in our analysis
(<90 days before and <30 days after date of enrolment),
this is a concern. CD4+ testing is an essential comple-
ment to WHO staging in accurately diagnosing HIV dis-
ease progression [19,20], but missing data due to various
program and patient level factors is a common challenge
in African programs [21-23]. A review of clinic data
from ICAP sites suggests that inadequate lab facilities,
frequent stock-outs of reagents, and machine breakdown
contribute to the lack of CD4+ data [24]. Newer tech-
nologies such as point-of-care testing and same day re-
sults for CD4+ [25] should be explored as a strategy to
improve availability of CD4+ data.
Despite the limitations with CD4+ testing, a large
number of patients initiated ART, and it is possible that
due to limited resources, CD4+ testing was deliberately
omitted where patients had advanced HIV disease. Ac-
cording to Tanzania and WHO guidelines used during
the study period [3,6,8,11], patients with clinically ad-
vanced HIV disease (WHO stage III or IV) could initiate
ART without a CD4+ cell count. In further analyses of
our study population, 84% of adults without CD4+ docu-
mentation at ART initiation were classified as WHO
stage III or IV, suggesting that patients missing CD4+
cell counts were more likely to have advanced disease
than patients receiving CD4+ testing. Consequently, the
median CD4+ at ART initiation observed in our study is
likely an overestimate of population CD4+ at ART initi-
ation if the less clinically ill patients preferentially had
CD4+ testing done.
We observed a modest increase in median CD4+ at
enrolment over time comparable to other sub-Saharan
Africa HIV programs [26,27], and suggesting healthier
populations accessing care. Our data showed no statisti-
cally significant increase in median CD4+ at ART initi-
ation, which could imply that greater efficiency is
needed in the ART initiation process, or that clinics re-
main overwhelmed by the very ill patients in need of
ART. This finding was unlike observations in other simi-
lar programs [26,28,29], but even in these programs, the
absolute increase in median CD4+ at ART initiation was
small. In Tanzania, implementation of changes in the
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from 200 to 350 cells/μL began in 2010/2011, and this
may contribute to the lack of change in our study obser-
vation period ending 2011. Our CD4+ trend data should
however be cautiously interpreted due to the significant
proportion of missing data. Further analyses of Optimal
Models data to explore time to, and predictors of, timely
ART initiation are planned.
There was a decline in stavudine use in the initial ART
regimen, particularly significant among adults. This is in
line with national and international guidelines that have
advocated for the phasing out of this drug due to toxic-
ities [7,14]. It is important that additional analyses con-
tinue to monitor this trend and also report the
proportion of patients currently using the drug. Stavu-
dine was not as widely used in initial pediatric-ART regi-
mens and the decline in use was less dramatic compared
to adults. This may be because in such resource-limited
settings, inadequate availability of pediatric ART formu-
lations often limits treatment choices [30].
One in three adults enrolled were male, and this did
not change significantly over time. Evaluations con-
ducted in other regions of Tanzania and Africa [4,31,32]
have reported limited male involvement, but in
Tanzania, this proportion is in line with the general
population where males comprise 37% of those HIV in-
fected [1]. Still, the impact of innovative strategies to en-
courage male access to HIV services, such as those
explored in PMTCT programs [33-36] should be exam-
ined in this setting. The proportion of children in the
study population did not increase significantly over time.
This in a country with over 80% unmet need for
pediatric ART [4] is a concerning finding and implies
that efforts to diagnose and enroll children into ART
care should be strengthened. Tanzania in collaboration
with ICAP and other development partners is facilitating
scaling up early infant diagnosis and creation of pediatric
and adolescent friendly services [37-39]. This may ex-
plain our data showing younger age and less advanced
children’s HIV disease at enrolment over time, perhaps
pointing to successful early testing and linkage to care
strategies implemented within PMTCT and VCT ser-
vices. It is also possible that potential increase in the
proportion of enrolled children expected from improved
case-finding of pregnant women and children through
scale-up of PMTCT services, early infant diagnosis pro-
grams and other pediatric focused initiatives was leveled
out by more successful PMTCT programs resulting in
fewer HIV-infected children.
The strengths of Optimal Models lie in the large sam-
ple of HIV-infected adults and children, and a variety of
sites represented from multiple regions of Tanzania over
a long observation period. The data are collected from
‘real-world’ settings: clinics and facilities where patientsreceived care, giving insight to grass roots activities. This
analysis serves as a baseline, and additional analyses
evaluating critical implementation issues are planned. A
limitation of this analysis was inadequate data to deter-
mine which clinics transferred-in patients were coming
from, possibly overestimating the overall number en-
rolled if patients transferred within the 44 study sites.
However, the impact of this overestimation is likely min-
imal since patients could potentially transfer-in from
over 900 other clinics in Tanzania and beyond. Further
review of the data indicated that transferring out of the
study clinics did not proportionally increase over time: it
declined from 17.9% to 13.1% to 5.9% in the respective
calendar year groups.
This analysis did not control for site-level effects when
testing for trends, however the entire patient population
at the study sites was used. Whereas the trends are indi-
cative of observations at the 44 study sites, the data can-
not be considered as applying to all clinics in Tanzania
more generally. Another limitation with this analysis
pertains to data quality barriers generally associated with
routine program data [40-43]. For example, it may well
be that CD4+ testing was done for more patients but
not captured in the patient records or the database. Rou-
tine data quality assessments are ongoing to continu-
ously improve the data and minimize missing and
erroneous data. These data encouragingly show im-
provements in data completeness for WHO stage and
point of entry over time, and there were minimal miss-
ing data for some key variables like gender and age at
enrolment.Conclusions
Over the early 7 years of HIV care and treatment pro-
gram implementation in Tanzania, there was an increase
in enrolment of pregnant women and adults and chil-
dren enrolled from PMTCT programs. The proportion
of adults and children with advanced HIV disease at en-
rolment declined, as did the stavudine use in the initial
ART regimen. Median pediatric age at enrolment and
ART initiation also declined. A large number of adults
and children were enrolled into HIV care and initiated
ART, demonstrating successful expansion of HIV ser-
vices in the country. However, many patients were miss-
ing documentation of CD4+ at enrolment and ART
initiation, an aspect that will require focus in further
program enhancements.Consent
This study was based on de-identified routinely collected
data. There was no interaction with patients for study
purposes. The protocol received non-human subjects re-
search designation and consent waiver under 45 CFR46.
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